Arista Wealth Management’s AbbVie ABBV Stock Holding History

Arista Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.97M	Buy	11,815 +316	+3%	+$68K	0.32%	40
2026 Q1	$2.5M	Buy	11,499 +83	+0.7%	+$18.4K	0.3%	43
2025 Q4	$2.61M	Buy	11,416 +2	+0%	+$456	0.32%	42
2025 Q3	$2.64M	Sell	11,414 -108	-0.9%	-$22K	0.33%	40
2025 Q2	$2.14M	Buy	+11,522	New	+$2.14M	0.3%	43

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arista Wealth Management's ABBV Position: Q2 2026 in Review

Arista Wealth Management increased its AbbVie (ABBV) stake by 2.7% in Q2 2026, buying an estimated $68K and bringing the position to 11,815 shares worth $2.97M. The position accounts for 0.32% of the portfolio, ranked #40.

Arista Wealth Management first reported a position in ABBV in Q2 2025 and has held it in 5 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Arista Wealth Management held 11,815 shares of AbbVie worth $2.97M as of Q2 2026.
Arista Wealth Management bought 316 AbbVie shares in Q2 2026, an estimated $68K.
AbbVie made up 0.32% of Arista Wealth Management's portfolio in Q2 2026, its #40 holding.
Arista Wealth Management first reported a position in AbbVie in Q2 2025 and has held it in 5 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Arista Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.